NasdaqGS:EXELBiotechs
How Investors Are Reacting To Exelixis (EXEL) Expanding CABOMETYX Approval for European Neuroendocrine Tumors
Earlier this month, Exelixis announced that its partner Ipsen received European Commission approval to market CABOMETYX for adults with unresectable or metastatic neuroendocrine tumors, following positive phase 3 data demonstrating significant clinical benefit.
This milestone expands CABOMETYX's geographic reach across all EU member states, Norway, Liechtenstein, and Iceland, opening new patient populations for Exelixis and its partners.
To explore the impact of this major regulatory...